Nivolumab Plus Ipilimumab for Unresectable Hepatocellular Carcinoma in Early Real-World Clinical Practice: A Multicenter Analysis of Efficacy and Safety
Cancers · 20.08.2026 · 18 (16) · 2703
DOI: 10.3390/cancers18162703 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 20.08.2026. Verfasst von Hironao Okubo und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Juntendo University Nerima Hospital, 3-1-10 Takanodai, Nerima-Ku, Tokyo 177-8521, Japan. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: To investigate early treatment outcomes, including tumor response, predictors of response, and safety of nivolumab plus ipilimumab (Nivo/Ipi) therapy for unresectable hepatocellular carcinoma (uHCC) in a multicenter setting.
Methods
We conducted a retrospective analysis of 64 Japanese patients with uHCC who received Nivo/Ipi therapy at participating centers between July 2025 and April 2026. Treatment efficacy was assessed according to RECIST version 1.1, and adverse events (AEs) were evaluated using CTCAE version 5.0.
Results
Among the 64 patients, 28 received first-line therapy, and 36 received later-line therapy. The median observation period was 5.4 months. The overall response rate (ORR) was significantly higher in the first-line group (60.7%) than in the later-line group (30.6%) (p = 0.016). ORRs according to CRAFITY score were 25.0% for score 0, 55.6% for score 1, and 53.8% for score 2. The ORR in patients with CRAFITY scores ≥ 1 was significantly higher than in patients with a CRAFITY score of 0 (55.0% vs. 25.0%; p = 0.022). Multivariable analysis of pretreatment variables predicting response revealed first-line treatment (OR 3.83, 95% CI 1.270–11.558; p = 0.017) and a CRAFITY score ≥ 1 (OR 4.02, 95% CI 1.232–13.106; p = 0.021) as significant independent factors. Immune-mediated AEs occurred in 70.3% of patients overall and were grade ≥ 3 in 35.9%.
Conclusions
Nivo/Ipi yielded a favorable response when used as first-line therapy. The baseline CRAFITY score may be a useful predictor of response to Nivo/Ipi therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Juntendo University Nerima Hospital, 3-1-10 Takanodai, Nerima-Ku, Tokyo 177-8521, Japan.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine (Omori), School of Medicine, Faculty of Medicine, Toho University, Omorinishi 6-11-1, Ota-Ku, Tokyo 143-8541, Japan.
- Department of Gastroenterology, Yokohama Hodogaya Central Hospital, 43-1 Kamadai-Cho, Hodogaya-Ku, Yokohama-Shi 240-8585, Japan.
- Gastroenterological Center, Yokohama City University Medical Center, 4-57, Urafune-Cho, Minami-Ku, Yokohama-Shi 232-0024, Japan.
- Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-Ku, Kumamoto 860-8556, Japan.
- Gastroenterology Medicine Center, Shonan Kamakura General Hospital, 1370-1 Okamoto, Kamakura-City 247-8533, Japan.
ORCID-Profile: Hironao Okubo, Haruki Uojima, Satoshi Narahara, Taito Fukushima, Satoshi Kobayashi, Kota Tsuruya, Tatehiro Kagawa, Hisashi Hidaka, Yasuhito Tanaka, Shin Maeda
Zitieren
APA
Okubo, H., Matsui, T., Chuma, M., Funaoka, A., Uojima, H., Narahara, S., Kobayashi, M., Ando, Y., Watanabe, T., Fukushima, T., Kobayashi, S., Hirano, K., Tsuruya, K., Kagawa, T., Iwasaki, S., Hidaka, H., Nagai, H., Tanaka, Y., Maeda, S., & Morimoto, M. (2026). Nivolumab Plus Ipilimumab for Unresectable Hepatocellular Carcinoma in Early Real-World Clinical Practice: A Multicenter Analysis of Efficacy and Safety. Cancers, 18(16), 2703. https://doi.org/10.3390/cancers18162703
Vancouver
Okubo H, Matsui T, Chuma M, Funaoka A, Uojima H, Narahara S, et al. Nivolumab Plus Ipilimumab for Unresectable Hepatocellular Carcinoma in Early Real-World Clinical Practice: A Multicenter Analysis of Efficacy and Safety. Cancers. 2026;18(16):2703. doi:10.3390/cancers18162703
BibTeX
@article{Okubo2026,
author = {Okubo, Hironao and Matsui, Teppei and Chuma, Makoto and Funaoka, Akihiro and Uojima, Haruki and Narahara, Satoshi and Kobayashi, Masahiro and Ando, Yuwa and Watanabe, Tsunamasa and Fukushima, Taito and Kobayashi, Satoshi and Hirano, Katsuharu and Tsuruya, Kota and Kagawa, Tatehiro and Iwasaki, Shuichiro and Hidaka, Hisashi and Nagai, Hidenari and Tanaka, Yasuhito and Maeda, Shin and Morimoto, Manabu},
title = {Nivolumab Plus Ipilimumab for Unresectable Hepatocellular Carcinoma in Early Real-World Clinical Practice: A Multicenter Analysis of Efficacy and Safety},
journal = {Cancers},
year = {2026},
volume = {18},
number = {16},
pages = {2703},
doi = {10.3390/cancers18162703}
}
EUVIMED